Last reviewed · How we verify
Epinephrin
At a glance
| Generic name | Epinephrin |
|---|---|
| Also known as | Adrenalin Chloride, Epipen, Adrenaline, Adrenalin |
| Sponsor | United States Naval Medical Center, San Diego |
| Target | Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Acute exacerbation of asthma
- Administration of Local Anesthetic Nerve Block
- Allergic Reactions
- Anaphylaxis
- Asthma management
- Bronchiectasis
- Bronchitis
- Dyspnea
- Exacerbation of asthma
- Hypotension associated with septic shock
- Local anesthesia, by infiltration
- Low blood pressure
- Open-angle glaucoma
- Pulmonary emphysema
- Wheezing
Common side effects
- Positional headaches
- Hypotension
- Backache
- Shivering
- Dizziness
- Drowsiness
- Lightheadedness
- Nervousness
- Apprehension
- Confusion
- Blurred or double vision
- Vomiting
Serious adverse events
- Convulsions
- Respiratory depression and arrest
- Unconsciousness
- Severe, persistent hypertension
- Cerebrovascular accidents
- Bradycardia
- Cardiac arrest
- Methemoglobinemia
- Chondrolysis with intra-articular infusion
- Persistent paresthesia lasting weeks to months or greater than one year
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (PHASE2)
- Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial (NA)
- Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Parenting and CAH - 21-hydroxylase Deficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epinephrin CI brief — competitive landscape report
- Epinephrin updates RSS · CI watch RSS
- United States Naval Medical Center, San Diego portfolio CI